Compare Capri Holdings Ltd (CPRI) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Cytokinetics Inc — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Cytokinetics Inc trades at $61.95 (market cap $8.62B). The key difference: Cytokinetics Inc is far larger — about 5.2× Capri Holdings Ltd's market cap, and Capri Holdings Ltd is more actively traded (3,722,279 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Cytokinetics Inc for 19 Days on average.
| CPRI | CYTK | |
|---|---|---|
Market Cap | $1.67B | $8.62B |
Volume | 3,722,279 | 2,594,626 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $87.26 |
52-Week Low | $12.71 | $54.76 |
Typical Hold Time | 41 Days | 19 Days |
Enterprise Value | $2.95B | $8.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $1.18 billion in 2025, though recent quarters have consistently beaten EPS estimates. Revenue has declined from $5.7 billion in 2022 to $4.44 billion in 2025, but management expects second-half growth driven by brand revitalization efforts at Michael Kors and Jimmy Choo.
The stock presents a mixed outlook with a low P/S ratio of 0.5 and a consensus price target of $20.57 offering potential upside. However, significant risks include persistent revenue declines, high debt levels, and competitive pressures in the luxury sector. Analyst sentiment is divided with 44% buy ratings versus 52% hold, reflecting uncertainty about the turnaround timeline.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
